View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
February 3, 2022

CRISPR, ViaCyte dose first subject in Phase I diabetes trial

An immune-evasive cell replacement therapy, VCTX210 could help patients in making their own insulin.

CRISPR Therapeutics and ViaCyte have dosed the first subject in the Phase I clinical trial of their investigational therapy VCTX210 to treat type 1 diabetes (T1D).

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Being developed jointly by the companies, VCTX210 is an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy.

It was created by combining gene-editing technology of CRISPR with stem cell expertise of ViaCyte to generate pancreatic cells that can evade recognition by the immune system. 

With this immune-evasive cell replacement therapy, patients will be able to make their own insulin.

The trial will evaluate the safety, tolerability and immune evasion of VCTX210 in individuals with T1D. 

CRISPR and ViaCyte are progressing this programme under the agreement currently in place.

Clinical trial investigator James Shapiro said: “We are excited to work with CRISPR Therapeutics and ViaCyte to carry out this historic, first-in-human transplant of gene-edited, stem cell-derived pancreatic cells for the treatment of diabetes designed to eliminate the need for immune suppression. 

“If this approach is successful, it will be a transformative treatment for patients with all insulin-requiring forms of diabetes.”

In September 2018, CRISPR and ViaCyte entered a partnership to discover, develop and market gene-edited allogeneic stem cell therapies to treat diabetes.

As per the deal, the companies had agreed to co-develop an immune-evasive stem cell line as an initial step to develop an allogeneic stem-cell derived product. 

The companies also assumed joint responsibility for the development and commercialisation of the identified product globally. 

ViaCyte obtained approval from the US Food and Drug Administration and Health Canada for its investigational new drug (IND) application in May 2017 to commence a trial to analyse PEC-Direct in T1D patients.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU